Answer
Welireg (belzutifan) is indicated for adults and paediatric patients aged 12 years and older with locally advanced, unresectable or metastatic pheochromocytoma or paraganglioma.
Sources for this answer
- WELIREG 40 mg film-coated tabletsMerck Sharp & Dohme (UK) Limited · emc · SmPC §4.1 Therapeutic Indications · Version 9Document updated
Sources checked